An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Latest Information Update: 18 Nov 2024
At a glance
- Drugs Magrolimab (Primary) ; Nivolumab (Primary) ; Fluorouracil; Irinotecan; Levofolinic acid; Oxaliplatin
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
Most Recent Events
- 11 Nov 2024 Planned End Date changed from 31 May 2025 to 31 Dec 2026.
- 11 Nov 2024 Planned primary completion date changed from 31 May 2025 to 31 Dec 2026.
- 07 Aug 2024 New trial record